Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Vandetanib thyroid carcinoma not applicable detail...
RET C634W Sorafenib thyroid carcinoma sensitive detail...
RET C634W Ponatinib thyroid carcinoma sensitive detail...
RET M918T Ponatinib thyroid carcinoma sensitive detail...
RET C634W Cabozantinib thyroid carcinoma sensitive detail...
Unknown unknown Obatoclax thyroid carcinoma not applicable detail...
Unknown unknown Sorafenib thyroid carcinoma not applicable detail...
Unknown unknown MLN8054 thyroid carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01208051 Phase Ib/II Cediranib + Lenalidomide Cediranib Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Active, not recruiting
NCT01655719 Phase II Pioglitazone Pioglitazone in Thyroid Cancers Completed
NCT02428712 Phase Ib/II PLX8394 A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors Active, not recruiting
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting
NCT02834013 Phase 0 Nivolumab + Ipilimumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting
NCT03181100 Phase II nab-paclitaxel Paclitaxel Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + nab-paclitaxel Atezolizumab + Vemurafenib + Cobimetinib Atezolizumab + Paclitaxel Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas Recruiting